CING Cingulate Inc. Loading... : Investor Sentiment and Bull/Bear Views
Loading chart...
Top Calls
No data yet
Price change since each call, adjusted for long/short direction. Results calculated:
Feed
10:29
Jan 06
Jan 06
PDUFA catalyst may re-rate tiny ADHD biotech
Cingulate's CTx-1301 for ADHD has a PDUFA date of 31 May and uses a well-known molecule, lowering clinical risk. A tiny ~$33M market cap could re-rate toward the $20B+ ADHD TAM if once-daily abuse-deterrent execution works; bull PTs range $25–60. Main risk is binary FDA/execution risk: approval is not guaranteed and the stock remains high-risk.
HIGH
About CING Investor Commentary
Across the available history and selected sources, Buzzberg tracks CING (Cingulate Inc.) across 1 sources: 1 bullish vs 0 bearish calls from 1 authors. Historical directional balance: 100% = 100 × (bullish − bearish) / all deduplicated idea records, including other directions. This is neither a probability of a price rise nor the share of bullish authors. 1 total trade idea tracked. Latest voices: u/Low-Pollution-262.